Please note, this OEL/ADE monograph also applies to rasagiline hydrochloride (CAS RN 136236-50-5). rasagiline mesylate (CAS RN 161735-79-1) rasagiline tartrate (CAS RN 136236-52-7), and rasagiline racemic (CAS RN 1875-50-9). Rasagiline is indicated to treat Parkinson’s disease. Rasagiline is an irreversible inhibitor of monoamine oxidase (MAO). Although the exact mechanisms of action are unknown, it is believed that rasagiline inhibits MAO type B (MAOB), the major form found in human brain tissue, causing an increase in extracellular levels of dopamine in the striatum. Increases in dopamine levels and subsequent increases in dopaminergic activity are most likely responsible for the beneficial effects observed in patients with Parkinson's disease.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Rasagiline, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.